GE HealthCare Receives FDA Clearance for SIGNA MRI Portfolio

- The newly cleared portfolio includes the SIGNA Sprint with Freelium, a 1.5T system, and the SIGNA Bolt, an advanced 3T scanner. Both are powered by the SIGNA One AI-driven workflow ecosystem. The SIGNA Sprint is designed to be more sustainable, using less than 1% of the helium of conventional MRI magnets, which can also lower operational costs. - This clearance positions GE HealthCare to compete with other major players in the MRI market, such as Siemens Healthineers and Philips Healthcare. Siemens and GE are considered the dominant players in the U.S. MRI market. The global MRI market is projected to grow from $6.56 billion in 2025 to $9.01 billion by 2030. - The integration of AI, as seen in the SIGNA One platform, is a key driver of innovation in the MRI market. AI is being used to automate image analysis, improve diagnostic accuracy, and enhance workflow efficiency. As of mid-2025, the FDA had approved over 870 radiology AI algorithms, with GE HealthCare holding 96 of those clearances. - The FDA classifies MRI systems as Class II (moderate risk) medical devices, requiring a 510(k) premarket notification. This process requires the manufacturer to demonstrate that the new device is "substantially equivalent" to a legally marketed predicate device. - There is a significant trend of diagnostic imaging shifting from hospitals to outpatient settings. Approximately 40% of all imaging volumes are now performed in outpatient centers, driven by the need for more convenient and cost-effective care. This has led health systems to develop strategies that coordinate imaging services across a network of inpatient and outpatient sites. - Reimbursement policies have influenced this shift in care. The Deficit Reduction Act of 2007 reduced technical component payments for advanced imaging in private offices, which initially led to an increase in volume in hospital outpatient departments. More recently, changes in the Medicare Hospital Outpatient Prospective Payment System (HOPPS) have made hospital ownership of off-campus imaging centers less financially attractive. - In response to these market dynamics, some health systems are forming joint ventures with large independent imaging companies. This allows hospitals to leverage the operational expertise of these companies while expanding their outpatient footprint. - Advanced imaging modalities are expected to see significant growth over the next decade, with projections of a 14% increase in volumes for procedures like MRI, CT, and PET scans in outpatient settings. This growth is fueled by an aging population and the increasing use of imaging in new therapies, such as those for Alzheimer's disease.